Union Demands CPPIB Ditch Brazil Water Privatization Involvement

The acquisition and privatization of a Brazil public water firm are socially harmful and economically risky moves, says CUPE.


Canada’s largest union is demanding that the $387.1 billion
Canada Pension Plan Investment Board (CPPIB) abandon its investment in a private water and sewage treatment service provider in Brazil. The Canadian Union of Public Employees (CUPE) said CPPIB is taking part in a “risky” sell-off of public water and sewage infrastructure being led by controversial President Jair Bolsonaro.

“The involvement of the CPPIB in support of Bolsonaro’s privatization program would serve to legitimize his disregard for the needs of the population,” the CUPE said in a letter earlier this month to CPPIB President and CEO John Graham.

At issue is the Canadian pension fund’s March acquisition of a 45% stake in Iguá  Saneamento, Brazil’s third-largest private water and sewage treatment service provider. CPPIB reported that it agreed to pay nearly 1.2 billion Brazilian real (US$217 million) for the stake.

“The opportunity to invest in a platform that can address the high demand for improved water and sanitation services in Brazil is a good fit with our diversified global infrastructure portfolio,” Scott Lawrence, managing director and head of infrastructure for CPPIB, said at the time.

Never miss a story — sign up for CIO newsletters to stay up-to-date on the latest institutional investment industry news.

But CUPE said Iguá Saneamento used CPPIB’s funds to buy a public water system being auctioned off in the state of Rio de Janeiro. The union also said there is “significant evidence” refuting claims that privatized water and wastewater services provide expanded and affordable access for poor and marginalized communities.

“It’s outrageous that our public pension plan is using workers’ retirement funds to profit from people’s need for clean water and safe sewage treatment,” CUPE National President Mark Hancock said in a statement. “These are human rights that are essential for survival. Access to water services is already fragile and unequal in Brazil. Privatization will make things worse and we want it scrapped.”

Nonprofit activist group Food & Water Watch says privatizing local water and sewer systems “usually does far more harm than good for our communities.” The group says that when private corporations buy or operate public water utilities, it is often done to fix municipal budget problems and aging water systems. “Unfortunately, this more often backfires, leaving communities with higher rates, worse service, job losses, and more,” the group said.

And according to nonprofit organization Water.org, there are currently 3 million Brazilians without access to safe water and 24 million Brazilians without access to improved sanitation. “There are still deep inequalities in access to water and sanitation among Brazil’s geographical regions, rural and urban communities, and households,” the group said.

A spokesman for CPPIB said the pension giant has no comment on the matter at this time.

Last week, unions in Brazil argued that the public water utility had not negotiated with the workers about mass layoffs and won a temporary injunction blocking the auction. The National Federation of Urban Workers said the privatization would result in thousands of workers losing their jobs. 

However, the auction went ahead anyway, and Iguá Saneamento’s bid won, giving it a contract of 35 years. In a release, Iguá said the public company will remain responsible for supplying clean and treated water to the metropolitan region ofRio de Janeiro. Iguá will be responsible for water distribution, collection, treatment, and sewage services in its designated concession area.

The release also said CPPIB will make a capital investment of up to R$1.7 billion (US$313 million) into Iguá, including the acquisition of both equity and convertible debentures, to fund the new concession.

Meanwhile, CUPE said it was disappointed that CPPIB went ahead with the investment, “ignoring warnings from unions and others about the many economic and social dangers of the deal.” CUPE argues that the risk doesn’t match the reward of CPPIB’s investment because of the political climate in Brazil. The group noted that presidential elections in 2022 could overturn the privatization and that there are currently several legal actions in Brazilian courts against the move.

“The current political environment makes any investment in Brazil’s public infrastructure inherently risky and damaging to your reputation,” CUPE said in its letter to Graham. “There is a very real possibility that public infrastructure sold off during the current government’s term could be brought back under public control under another government, exposing investors to losses.”

CUPE also said it believes acquiring the Iguá Saneamento stake exposes CPPIB to involvement in potential violations of human rights. In 2016 CPPIB added human rights as one of its focus areas when engaging with companies it invests in.

“We believe that strong human rights practices contribute to long-term value and engaging with companies in our portfolio on this topic is therefore an important part of our strategy to maximize long-term returns,” CPPIB said at the time.

Related Stories:

CPPIB Chief Mark Machin Exits Amid Vaccine Uproar

Pattern Energy Calls Lawsuit Challenging CPPIB Acquisition a ‘PR Stunt’

Top Canadian Pension Plan and US Apartment Operator to Build Brazilian Housing

Tags: , , , , , , , , ,

Mubadala and Others Pledge Big Money for UK-Based AI Drug Discovery Firm

Exscientia has just closed a $225 million Series D funding round, enlisting giant institutional investors.


A UK-based drug discovery company called Exscientia, which uses artificial intelligence (AI) to design pharmaceuticals, just closed a $225 million Series D funding round. Its investors include the United Arab Emirates’ sovereign wealth fund, Mubadala Investment Company, along with SoftBank, Novo Holdings, and Blackrock-managed funds.

The clinical stage pharmatech company was also given an additional $300 million equity commitment from SoftBank Vision Fund 2 that Exscientia can draw from at its discretion, the firm said last week. Also last week, the British firm received an innovation award from Queen Elizabeth II. 

Abu Dhabi-based Mubadala has been making a number of tech-oriented investments lately. Last year, the sovereign wealth fund and the Canadian Pension Plan Investment Board (CPPIB) led a $2.25 billion funding round into Waymo, an Alphabet subsidiary developing driverless cars.

This past fall, it made a solo $2 billion investment into private equity firm Silver Lake to develop a 25-year investment strategy. It’s also turning parking lots into hubs for restaurants and other services, after leading a $700 growth equity round into real estate and technology firm REEF.

Want the latest institutional investment industry
news and insights? Sign up for CIO newsletters.

“With a vision to find faster and smarter ways to discover new and better drugs, the UK-based company has developed a unique AI platform that combines with cutting edge science to bring new drugs to market more efficiently,” read a statement from Mubadala’s Twitter.

Bio and pharmatech is a growing area of interest for many investors. Venture capital deal activity in 2021 for the two sectors is expected to jump to more than $20 billion, according to Pitchbook data. Increasing chronic diseases in aging populations, as well as the pandemic, have boosted interest in the sector. 

But the drug approval process is often time consuming and costly, for both manufacturers and investors. Applications companies submit to the US Food and Drug Administration (FDA) can take more than two years to be approved. 

Exscientia is aiming to hasten the drug development process using artificial intelligence. Funding for the startup will help it continue to build out its technological capabilities, which will use patient data to design drugs at a molecular scale. 

Since its founding, the startup has brought seven precision-designed drugs to development candidacy in about a year. 

Other investors in the company include Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou, and Bristol-Myers Squibb.  

Related Stories: 

As VC Soars, Main Sequence Attracts Temasek, Hostplus for Second Fund

Bill Seeks to Allow 403(b) Plans to Use Collective Investment Trusts

NY State Pension Commits to $400 Million in Sustainable Investments

Tags: , , , , , ,

«